11 results
Comparison of oral anticoagulant agents (DOACS + Warfarin)

Reference: ENLS 2017 Pharmacotherapy. Neurocritical Care Journal.

#DOAC #Dosing #Oral
Comparison of oral ... #DOAC #Dosing #Oral ... Anticoagulation #Comparison ... #Table #Pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
• Itraconazole oral ... • Posaconazole oral ... • Itraconazole oral ... opportunistic #infections ... #HIVAIDS #pharmacology
IDSA Recommendations for Treating Herpes Simplex Virus (HSV) Infections in HIV-AIDS
Treating Orolabial Lesions (Duration: 5–10 days)
IDSA Recommendations ... Simplex Virus (HSV) Infections ... regress, change to oral ... HerpesSimplex #HSV #IDSA ... #HIVAIDS #pharmacology
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
Rybelsus (oral semaglutide ... ) - First Oral GLP ... first (& only) oral ... Oral semaglutide ... #Rybelsus #oral
IDSA - Clinical Strategy to Build an Individualized Treatment Regimen for Multi-Drug Resistant Tuberculosis (MDR-TB)
 •
are contacts of infectious ... five effective oral ... If needed or if oral ... antimicrobials #regimens #pharmacology ... #dosing #idsa #
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
IDSA Recommendations ... Please refer to the table ... Guidelines for dosing ... Tuberculosis #TB #IDSA ... #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Managing Cryptosporidiosis in HIV-AIDS
Preventing Chronic Cryptosporidiosis:
 • Because chronic cryptosporidiosis occurs
IDSA Recommendations ... • Aggressive oral ... Cryptosporidiosis #IDSA ... opportunistic #infections ... #HIVAIDS #pharmacology
It is important to recognize Acute Decompensated Heart Failure (ADHF) as more than just simply a
transitioning to oral ... #differential #algorithm ... #management #cardiology ... #treatment #table ... icu #clinical #pharmacology
IDSA Recommendations for Preventing and Treating HHV-8 Diseases—Kaposi Sarcoma (KS), Primary Effusion Lymphoma (PEL), Multicentric Castleman’s
IDSA Recommendations ... specialist) + ART • Oral ... KaposiSarcoma #Castlemans #IDSA ... opportunistic #infections ... #HIVAIDS #pharmacology
Preoperative Risk Evaluation

Major Pre-Op Questions:
1. Does the patient have any modifiable risk factors that could be
Skin exam for infection ... neuroexam - Oral ... event, follow ACC algorithm ... Stable patients ... one post op Cardiology